HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells.

AbstractPURPOSE:
Nonsteroidal anti-inflammatory drugs (NSAID) are promising chemopreventive agents against colon and other cancers. However, the molecular basis mediated by NSAIDs for chemoprevention has not been fully elucidated. Environmental carcinogens induce DNA mutation and cellular transformation; therefore, we examined the effect of NSAIDs on carcinogenesis mediated by the aryl hydrocarbon receptor signaling pathway. In this study, we investigated the activities of a new class of NSAIDs containing dithiolethione moieties (S-NSAID) on both arms of carcinogenesis.
EXPERIMENTAL DESIGN:
We investigated the effects of the S-NSAIDs, S-diclofenac and S-sulindac, on carcinogen activation and detoxification mechanisms in human hepatoma HepG2 and human colonic adenocarcinoma LS180 cells.
RESULTS:
We found that S-diclofenac and S-sulindac inhibited the activity and expression of the carcinogen activating enzymes, cytochromes P-450 (CYP) CYP1A1, CYP1B1, and CYP1A2. Inhibition was mediated by transcriptional regulation of the aryl hydrocarbon receptor (AhR) pathway. The S-NSAIDs down-regulated carcinogen-induced expression of CYP1A1 heterogeneous nuclear RNA, a measure of transcription rate. Both compounds blocked carcinogen-activated AhR from binding to the xenobiotic responsive element as shown by chromatin immunoprecipitation. S-diclofenac and S-sulindac inhibited carcinogen-induced CYP enzyme activity through direct inhibition as well as through decreased transcriptional activation of the AhR. S-sulindac induced expression of several carcinogen detoxification enzymes of the glutathione cycle including glutathione S-transferase A2, glutamate cysteine ligase catalytic subunit, glutamate cysteine ligase modifier subunit, and glutathione reductase.
CONCLUSIONS:
These results indicate that S-diclofenac and S-sulindac may serve as effective chemoprevention agents by favorably balancing the equation of carcinogen activation and detoxification mechanisms.
AuthorsSara E Bass, Pawel Sienkiewicz, Christopher J Macdonald, Robert Y S Cheng, Anna Sparatore, Piero Del Soldato, David D Roberts, Terry W Moody, David A Wink, Grace Chao Yeh
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 15 Issue 6 Pg. 1964-72 (Mar 15 2009) ISSN: 1078-0432 [Print] United States
PMID19276279 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)
Chemical References
  • 2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester
  • Anti-Inflammatory Agents, Non-Steroidal
  • Anticarcinogenic Agents
  • Polychlorinated Dibenzodioxins
  • RNA, Messenger
  • Receptors, Aryl Hydrocarbon
  • S-sulindac
  • Thiones
  • Diclofenac
  • Sulindac
  • Cytochrome P-450 CYP1A1
Topics
  • Anti-Inflammatory Agents, Non-Steroidal (pharmacology)
  • Anticarcinogenic Agents (pharmacology)
  • Cell Line, Tumor
  • Colorectal Neoplasms (enzymology, pathology)
  • Cytochrome P-450 CYP1A1 (antagonists & inhibitors, genetics)
  • Diclofenac (analogs & derivatives, pharmacology)
  • Humans
  • Liver Neoplasms (enzymology, pathology)
  • Polychlorinated Dibenzodioxins (pharmacology)
  • RNA, Messenger (analysis)
  • Receptors, Aryl Hydrocarbon (antagonists & inhibitors)
  • Sulindac (analogs & derivatives, pharmacology)
  • Thiones (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: